OTC Markets Group Grants Evofem Additional Time to File Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2022
Evofem Biosciences, Inc. (OTCQB: EVFM) has been granted an extension by the OTC Markets Group to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022.
Rhea-AI Summary
Evofem Biosciences, Inc. (OTCQB: EVFM) has been granted an extension by the OTC Markets Group to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022. The new deadline for submission is January 6, 2023, extending from the previous date of December 29, 2022. This extension comes as the company continues to navigate its filing obligations amidst ongoing developments in its business, particularly regarding its FDA-approved product, Phexxi.
Positive
- Extension granted for filing the 10-Q provides additional time for compliance.
Negative
- Delay in filing could indicate potential financial distress or operational challenges.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Dec. 29, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that it has been granted additional time by the OTC Markets Group to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (the "10-Q"). Previously, the OTC Markets Group provided until December 29, 2022 to file the 10-Q . The extended deadline is now January 6, 2023.
About Evofem
Evofem Biosciences, Inc., is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com and evofem.com.
Phexxi® is a registered trademark of Evofem Biosciences, Inc.
About Phexxi
Phexxi is an on-demand method of birth control used to prevent pregnancy. Phexxi is not effective when used after sex. For more information about Phexxi, talk to your healthcare provider and see full Product Information at www.phexxi.com.
Contacts
Investors:
Amy Raskopf
SVP, Investor Relations
Evofem Biosciences, Inc.
araskopf@evofem.com
(917) 673-5775
Media:
media@evofem.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/otc-markets-group-grants-evofem-additional-time-to-file-quarterly-report-on-form-10-q-for-the-quarter-ended-september-30-2022-301711204.html
SOURCE Evofem Biosciences, Inc.